Myriad Genetics Inc. (NASDAQ:MYGN) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 22,281,030 shares, a decline of 6.6% from the October 31st total of 23,864,590 shares. Currently, 32.9% of the shares of the stock are short sold. Based on an average daily volume of 2,452,432 shares, the short-interest ratio is currently 9.1 days.

A number of analysts have recently issued reports on the stock. Gabelli downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $46.00 to $32.00 in a report on Wednesday, August 10th. Stephens downgraded shares of Myriad Genetics from an “overweight” rating to an “equal weight” rating in a report on Wednesday, November 2nd. Morgan Stanley dropped their price objective on shares of Myriad Genetics from $25.00 to $21.00 and set an “underweight” rating for the company in a report on Wednesday, August 10th. Zacks Investment Research downgraded shares of Myriad Genetics from a “hold” rating to a “sell” rating in a report on Tuesday, October 25th. Finally, Jefferies Group dropped their price objective on shares of Myriad Genetics from $34.00 to $20.00 and set a “hold” rating for the company in a report on Thursday, August 11th. Five analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $31.00.

In other news, Director John T. Henderson sold 30,000 shares of the business’s stock in a transaction on Monday, September 12th. The shares were sold at an average price of $20.49, for a total transaction of $614,700.00. Following the completion of the transaction, the director now directly owns 49,493 shares in the company, valued at approximately $1,014,111.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Myriad Genetics by 7.7% in the first quarter. Geode Capital Management LLC now owns 527,592 shares of the company’s stock worth $19,747,000 after buying an additional 37,842 shares during the last quarter. Squarepoint Ops LLC boosted its position in shares of Myriad Genetics by 210.3% in the first quarter. Squarepoint Ops LLC now owns 21,100 shares of the company’s stock worth $790,000 after buying an additional 14,300 shares during the last quarter. BlueMountain Capital Management LLC acquired a new position in shares of Myriad Genetics during the first quarter worth approximately $509,000. BNP Paribas Arbitrage SA boosted its position in shares of Myriad Genetics by 28.6% in the second quarter. BNP Paribas Arbitrage SA now owns 19,992 shares of the company’s stock worth $612,000 after buying an additional 4,449 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Myriad Genetics by 2.7% in the second quarter. Fisher Asset Management LLC now owns 92,236 shares of the company’s stock worth $2,957,000 after buying an additional 2,453 shares during the last quarter.

Myriad Genetics (NASDAQ:MYGN) opened at 17.46 on Monday. The stock has a market cap of $1.19 billion, a PE ratio of 13.50 and a beta of 0.42. Myriad Genetics has a 12 month low of $15.92 and a 12 month high of $44.57. The company’s 50 day moving average is $18.31 and its 200 day moving average is $25.44.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, November 1st. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by $0.02. Myriad Genetics had a return on equity of 13.98% and a net margin of 11.38%. The business earned $177.50 million during the quarter, compared to analysts’ expectations of $172.31 million. During the same period in the previous year, the business earned $0.41 earnings per share. The business’s quarterly revenue was down 3.3% on a year-over-year basis. On average, analysts anticipate that Myriad Genetics will post $0.99 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2016/11/28/myriad-genetics-inc-mygn-short-interest-update.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

5 Day Chart for NASDAQ:MYGN

Receive News & Stock Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related stocks with our FREE daily email newsletter.